Research And Markets Research And Markets

Search for: "Harrisburg, PA Market Overview"

Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight

The December 2013 approval of Gilead's once daily oral nucleotide inhibitor Sovaldi marks a significant step in the treatment of hepatitis C (HCV) With efficacy over 90% in GT1/2/3/4 patients, this...

Published:  December 2013
Price:  From EURUSDGBP
Loading Indicator